These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 8910322

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
    Saenko EL, Scandella D.
    J Biol Chem; 1997 Jul 18; 272(29):18007-14. PubMed ID: 9218428
    [Abstract] [Full Text] [Related]

  • 5. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
    Peerlinck K, Jacquemin MG, Arnout J, Hoylaerts MF, Gilles JG, Lavend'homme R, Johnson KM, Freson K, Scandella D, Saint-Remy JM, Vermylen J.
    Blood; 1999 Apr 01; 93(7):2267-73. PubMed ID: 10090936
    [Abstract] [Full Text] [Related]

  • 6. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
    Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E.
    Blood; 1995 Sep 01; 86(5):1811-9. PubMed ID: 7544643
    [Abstract] [Full Text] [Related]

  • 7. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex.
    Saenko EL, Shima M, Sarafanov AG.
    Trends Cardiovasc Med; 1999 Oct 01; 9(7):185-92. PubMed ID: 10881749
    [Abstract] [Full Text] [Related]

  • 8. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
    Saenko EL, Shima M, Rajalakshmi KJ, Scandella D.
    J Biol Chem; 1994 Apr 15; 269(15):11601-5. PubMed ID: 7512568
    [Abstract] [Full Text] [Related]

  • 9. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
    Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P.
    Blood; 2007 Dec 15; 110(13):4234-42. PubMed ID: 17848617
    [Abstract] [Full Text] [Related]

  • 10. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.
    Gale AJ, Radtke KP, Cunningham MA, Chamberlain D, Pellequer JL, Griffin JH.
    J Thromb Haemost; 2006 Jun 15; 4(6):1315-22. PubMed ID: 16706977
    [Abstract] [Full Text] [Related]

  • 11. The effect of thrombin on the complex between factor VIII and von Willebrand factor.
    Hamer RJ, Koedam JA, Beeser-Visser NH, Sixma JJ.
    Eur J Biochem; 1987 Sep 01; 167(2):253-9. PubMed ID: 3113951
    [Abstract] [Full Text] [Related]

  • 12. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.
    Li X, Gabriel DA.
    Biochemistry; 1997 Sep 02; 36(35):10760-7. PubMed ID: 9271507
    [Abstract] [Full Text] [Related]

  • 13. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
    Batsuli G, Deng W, Healey JF, Parker ET, Baldwin WH, Cox C, Nguyen B, Kahle J, Königs C, Li R, Lollar P, Meeks SL.
    Blood; 2016 Oct 20; 128(16):2055-2067. PubMed ID: 27381905
    [Abstract] [Full Text] [Related]

  • 14. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K, Nogami K, Shima M.
    Br J Haematol; 2013 Oct 20; 163(1):104-11. PubMed ID: 23889549
    [Abstract] [Full Text] [Related]

  • 15. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G, Ito J, Mercer R, Baldwin WH, Cox C, Parker ET, Healey JF, Lollar P, Meeks SL.
    J Thromb Haemost; 2018 Sep 20; 16(9):1779-1788. PubMed ID: 29981270
    [Abstract] [Full Text] [Related]

  • 16. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.
    Precup JW, Kline BC, Fass DN.
    Blood; 1991 May 01; 77(9):1929-36. PubMed ID: 1902121
    [Abstract] [Full Text] [Related]

  • 17. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.
    Jacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, Bakkus M, Thielemans K, Arnout J, Peerlinck K, Gilles JG, Vermylen J, Saint-Remy JM.
    Blood; 1998 Jul 15; 92(2):496-506. PubMed ID: 9657749
    [Abstract] [Full Text] [Related]

  • 18. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.
    Shima M, Yoshioka A, Nakajima M, Nakai H, Fukui H.
    Br J Haematol; 1992 Aug 15; 81(4):533-8. PubMed ID: 1390241
    [Abstract] [Full Text] [Related]

  • 19. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
    Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K.
    Thromb Haemost; 1996 Nov 15; 76(5):749-54. PubMed ID: 8950785
    [Abstract] [Full Text] [Related]

  • 20. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
    Yada K, Nogami K, Takeyama M, Ogiwara K, Wakabayashi H, Shima M.
    J Thromb Haemost; 2015 Oct 15; 13(10):1843-53. PubMed ID: 26278069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.